Skip to main content

News

News
10/31/2024
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial, patients with myelofibrosis previously treated with ruxolitinib demonstrated superior spleen volume reduction and symptom response when treated with fedratinib compared with best available therapy.
According to a phase 3 trial,...
10/31/2024
Oncology
News
10/10/2024
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated, improved spleen and symptom responses, and reduced transfusion burden among a subgroup of patients with JAK inhibitor-naive myelofibrosis, determined an analysis of the phase 3 SIMPLIFY-1 study.
Momelotinib was well-tolerated,...
10/10/2024
Oncology
News
10/04/2024
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell transfusion dependence and concurrent JAK inhibitor treatment, concluded a recent phase 2 trial.
Luspatercept improved anemia and...
10/04/2024
Oncology
News
10/02/2024
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
According to a prospective phase 2 trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained declines in circulating CD34+ cell counts were associated with response to hypomethylating agent decitabine treatment for...
According to a prospective phase...
10/02/2024
Oncology
News
08/29/2024
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Sovleplenib, a novel spleen tyrosine kinase inhibitor, demonstrated a clinically meaningful, sustained platelet response among patients with chronic primary immune thrombocytopenia, according to results from a phase 3 study.
Sovleplenib, a novel spleen...
08/29/2024
Oncology
News
08/14/2024
Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...
Triple-negative myelofibrosis was found to be continually associated with decreased survival in addition to enhanced aggressive behavior with higher rates of leukemic transformation as well as a shorter duration of response to ruxolitinib,...
Triple-negative myelofibrosis...
08/14/2024
Oncology
Conference Coverage
05/31/2024

Amber Denham

Amber Denham
Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.
Long-term follow-up results from a phase 2 trial highlight the promising efficacy of azacitidine in combination with ruxolitinib for patients with myelofibrosis.
Long-term follow-up results from...
05/31/2024
Oncology
Conference Coverage
05/30/2024

Amber Denham

Amber Denham
Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...
Pelabresib plus ruxolitinib significantly reduced splenomegaly and improved anemia and bone marrow fibrosis compared with placebo plus ruxolitinib among JAK-inhibitor-treatment-naïve patients with myelofibrosis, according to updated phase 3...
Pelabresib plus ruxolitinib...
05/30/2024
Oncology
News
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology
News
03/22/2024

Jordan Kadish

Jordan Kadish
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the phase 2 REVIVE trial, rusfertide treatment demonstrated improved responses and decreased erythrocytosis among patients with polycythemia vera.
According to findings from the...
03/22/2024
Oncology